Quality of life in ovarian cancer patients: Comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study
Quality of life in ovarian cancer patients: Comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study
复制标题
DOI：
10.1200/jco.2004.08.080
复制
发表时间：
2004-11-15
影响因子：
45.3
通讯作者：
Eisenhauer, E
中科院分区：
文献类型：
--
作者：
Bezjak, A;Tu, DS;Eisenhauer, E
目的正式的生活质量(QOL)评估可能有助于了解患者症状的重要信息。尽管卵巢癌的全身化疗试验很多，但关于其对生活质量影响的报道很少。患者和方法在一项组间随机试验中评估了晚期卵巢癌患者的生活质量，比较了紫杉醇+顺铂和环磷酰胺+顺铂。在加拿大累积的152名符合条件的患者完成了欧洲癌症研究和治疗组织生活质量问卷C30和一份试验专用核对表，在基线(手术清除后)以及在化疗期间和之后定期进行。计算两组患者随时间变化的平均分。结果患者对生活质量问卷填写的依从性良好(81%~93%)。总体而言，化疗后立即(周期1的第8天)的生活质量领域出现恶化，随后在治疗期间，与基线(变化分数大于或等于10)相比，两臂的许多领域和项目的临床有意义的改善，包括全球生活质量、情绪功能、社会功能、疲劳、疼痛、睡眠、便秘、食欲、腹部肿胀和腹部痉挛。在随访期间，全球生活质量的改善持续存在。紫杉醇组有更多的神经感觉效应和肌肉疼痛；然而，这并没有对整体或其他领域的生活质量产生负面影响，并且在化疗完成后有所改善。结论两个治疗组的生活质量测量都比基线有所改善。紫杉醇较大的神经和肌肉毒性并未对生活质量产生不利影响。生活质量数据可以提供有关症状经验及其时间进程的有用信息，这可能有助于患者和医生讨论治疗的预期效果。(C)2004年，由美国临床肿瘤学会提供。
Purpose Formal quality-of-life (QOL) assessments may contribute important information on patient symptoms. Despite many trials of systemic chemotherapy in ovarian cancer, reports of its effect on QOL are few.Patients and Methods QOL was assessed in an Intergroup randomized trial comparing paclitaxel plus cisplatin to cyclophosphamide plus cisplatin in women with advanced ovarian cancer. One hundred fifty-two eligible patients accrued in Canada completed the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 and a trial-specific checklist at baseline (after surgical debulking) and at regular intervals during and after chemotherapy. Mean change scores over time in the two arms were calculated.Results Compliance with QOL questionnaire completion was excellent (81% to 93%). In general, deterioration was seen in the QOL domains immediately after chemotherapy (day 8 of cycle 1), followed by clinically meaningful improvements compared with baseline (change scores greater than or equal to 10) in both arms during the treatment period in a number of domains and items, including global QOL, emotional function, social function, fatigue, pain, sleep, constipation, appetite, abdominal swelling, and abdominal cramps. Improvements in global QOL persisted for the duration of follow-up. More neurosensory effects and myalgia were documented in the paclitaxel arm; however, this did not adversely affect global or other domains of QOL and improved once chemotherapy was completed.Conclusion Improvement from baseline in QOL measures was seen in both treatment arms. The greater neurologic and muscle toxicity of paclitaxel did not adversely influence QOL. QOL data can contribute useful information on the experience of symptoms and their time course, which may assist patients and physicians in their discussion about the anticipated effects of therapy. (C) 2004 by American Society of Clinical Oncology.